Received Apr 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 55ZX7 | — |
Administration of only the liquid component; Administration of only the liquid component; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ABCWY NVS (Penmenvy) (batch number 55ZX7, expiry date 20-NOV-2026) for prophylaxis. On 06-APR-2026, the patient received the 1st dose of Penmenvy. On 06-APR-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate preparation of medication (Verbatim: Administration of only the liquid component) and inappropriate dose of vaccine administered (Verbatim: Administration of only the liquid component). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-APR-2026 The reporter reported that there was error during administration of Penmenvy to a patient. The medical assistant administered only the liquid component of the vaccine. This was the patient's first dose of Penmenvy, and it was administered on 06-APR-2026. No further details were provided.